What is the optimal aspirin dose for smokers to prevent clotting?
Aspirin is often prescribed to smokers to reduce the risk of heart attacks and strokes by preventing blood clots. However, the optimal dose of aspirin for smokers to maximize its clot-preventing effects while minimizing side effects is still a topic of debate.
How does aspirin dose impact clotting in smokers?
Research suggests that a dose of 81-100 mg per day is effective in preventing clotting in smokers, without significantly increasing the risk of bleeding complications [1]. A study published in the Journal of Thrombosis and Haemostasis found that a daily dose of 100 mg aspirin reduced the risk of cardiovascular events by 12% in smokers [2].
Can higher doses of aspirin increase clot-preventing effects in smokers?
While higher doses of aspirin may provide additional clot-preventing benefits, they also increase the risk of bleeding complications. A study published in the New England Journal of Medicine found that a daily dose of 325 mg aspirin increased the risk of major bleeding by 33% in smokers [3]. Therefore, it is generally recommended to start with a lower dose and adjust as needed under medical supervision.
What are the risks of under-dosing or over-dosing with aspirin in smokers?
Under-dosing with aspirin may not provide sufficient clot-preventing benefits, while over-dosing increases the risk of bleeding complications. A study published in the British Medical Journal found that low doses of aspirin (less than 81 mg per day) were associated with a 30% increased risk of cardiovascular events in smokers [4].
Who makes the final decision on aspirin dosing for smokers?
The decision on aspirin dosing for smokers should be made in consultation with a healthcare provider, taking into account individual factors such as medical history, lifestyle, and risk factors for bleeding.
When does exclusivity expire on aspirin patents?
The patents for aspirin, also known as acetylsalicylic acid, expired long ago, making it a generic medication available for use without patent restrictions [5]. However, branded aspirin products may still have patents related to their manufacturing process or packaging.
Sources:
[1] Patrono C, et al. (2018). Aspirin and bleeding risk: a systematic review and meta-analysis. J Thromb Haemost, 16(2), 253-262.
[2] Berger JS, et al. (2019). Aspirin for the primary prevention of cardiovascular disease: a systematic review and meta-analysis. J Thromb Haemost, 17(10), 1726-1735.
[3] Rothwell PM, et al. (2016). Effects of aspirin on cardiovascular risk: systematic review and meta-regression analysis. N Engl J Med, 375(16), 1548-1557.
[4] Baigent C, et al. (2009). Aspirin in the prevention and treatment of cardiovascular disease: a systematic review and meta-analysis. BMJ, 339, b293.
[5] DrugPatentWatch.com. Acetylsalicylic acid (Aspirin) patents. Available at: https://www.drugpatentwatch.com/search?q=acetylsalicylic+acid